drugset / Trial / NCT06481410
Efficacy and Safety of Methylene Blue in the Treatment of Severe Septic Shock
Unknown
488 enrolled
First Affiliated Hospital of Zhejiang University
First Affiliated Hospital, Sun Yat-Sen University · collabGUI LIN PEOPLE'S HOSPITAL · collabHangzhou Yuhang District Second People's Hospital · collabNingbo Medical Center Lihuili Hospital · collabPeople's Hospital of Guangxi Zhuang Autonomous Region · collabTaizhou Enze Medical Center Group · collabThe First People's Hospital of Huzhou · collabThe second Nanning People's Hospital · collabWuming Hospital of Guangxi Medical University · collabYuyao People's Hospital · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The goal of this clinical trial is to investigate whether methylene blue injection can safely and effectively improve the survival rate of patients with severe septic shock, shorten the duration of norepinephrine use, reduce the dosage of vasopressors, promptly correct hemodynamics, and improve tissue perfusion and organ function impairment.
Timeline
- Start
- 2024-06-22
- Primary completion
- 2026-06-20
- Completion
- 2026-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methylene Blue | Diagnostic / imaging agent | 0.25 mg/kg | — |